Login to Your Account



In The Clinic NEWS

Shares of Puma Biotechnology Inc. (NYSE:PBYI) rose 20.3 percent Friday on word that the company has submitted an FDA NDA for its lead candidate, neratinib.

The FDA switcheroo that's holding up Elite Pharmaceuticals Inc.'s Sequestox, the firm's abuse-deterrent opioid for pain "should not take that long" to resolve, CEO Nasrat Hakim said during a conference call.

DUBLIN – Pharming Group NV gave its weary investors a smidgen of hope Monday, with phase II trial news supporting the efficacy of its lead drug Ruconest in treating acute attacks of hereditary angioedema.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: